AIM vs. CVKD, CLSD, AKTX, ALLR, NEUP, RLYB, XCUR, ENLV, ALVR, and LIXT
Should you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include Cadrenal Therapeutics (CVKD), Clearside Biomedical (CLSD), Akari Therapeutics (AKTX), Allarity Therapeutics (ALLR), Neuphoria Therapeutics (NEUP), Rallybio (RLYB), Exicure (XCUR), Enlivex Therapeutics (ENLV), AlloVir (ALVR), and Lixte Biotechnology (LIXT). These companies are all part of the "pharmaceutical products" industry.
AIM ImmunoTech vs. Its Competitors
Cadrenal Therapeutics (NASDAQ:CVKD) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.
Cadrenal Therapeutics has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. Cadrenal Therapeutics' return on equity of -265.37% beat AIM ImmunoTech's return on equity.
In the previous week, Cadrenal Therapeutics had 5 more articles in the media than AIM ImmunoTech. MarketBeat recorded 7 mentions for Cadrenal Therapeutics and 2 mentions for AIM ImmunoTech. Cadrenal Therapeutics' average media sentiment score of 0.66 beat AIM ImmunoTech's score of 0.60 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.
Cadrenal Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.
Cadrenal Therapeutics has higher earnings, but lower revenue than AIM ImmunoTech. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.
Cadrenal Therapeutics presently has a consensus price target of $32.00, suggesting a potential upside of 138.98%. AIM ImmunoTech has a consensus price target of $275.00, suggesting a potential upside of 10,944.18%. Given AIM ImmunoTech's stronger consensus rating and higher possible upside, analysts plainly believe AIM ImmunoTech is more favorable than Cadrenal Therapeutics.
7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 26.1% of Cadrenal Therapeutics shares are held by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Cadrenal Therapeutics beats AIM ImmunoTech on 8 of the 15 factors compared between the two stocks.
Get AIM ImmunoTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AIM ImmunoTech Competitors List
Related Companies and Tools
This page (NYSE:AIM) was last updated on 9/16/2025 by MarketBeat.com Staff
Free AIM Stock Alerts